These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12115351)

  • 1. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.
    Fuchs CS; Clark JW; Ryan DP; Kulke MH; Kim H; Earle CC; Vincitore M; Mayer RJ; Stuart KE
    Cancer; 2002 Jun; 94(12):3186-91. PubMed ID: 12115351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.
    Yang TS; Lin YC; Chen JS; Wang HM; Wang CH
    Cancer; 2000 Aug; 89(4):750-6. PubMed ID: 10951336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.
    Parikh PM; Fuloria J; Babu G; Doval DC; Awasthy BS; Pai VR; Prabhakaran PS; Benson AB
    Trop Gastroenterol; 2005; 26(3):115-8. PubMed ID: 16512457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.
    Kubicka S; Rudolph KL; Tietze MK; Lorenz M; Manns M
    Hepatogastroenterology; 2001; 48(39):783-9. PubMed ID: 11462924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine.
    Ulrich-Pur H; Kornek GV; Fiebiger W; Schüll B; Raderer M; Scheithauer W
    Oncology; 2001; 60(4):313-5. PubMed ID: 11408798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial.
    Yang TS; Wang CH; Hsieh RK; Chen JS; Fung MC
    Ann Oncol; 2002 Nov; 13(11):1771-8. PubMed ID: 12419750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.
    Guan Z; Wang Y; Maoleekoonpairoj S; Chen Z; Kim WS; Ratanatharathorn V; Reece WH; Kim TW; Lehnert M
    Br J Cancer; 2003 Nov; 89(10):1865-9. PubMed ID: 14612894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
    Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
    Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
    Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J
    Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.
    Srimuninnimit V; Sriuranpong V; Suwanvecho S
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):255-60. PubMed ID: 24810940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
    Louafi S; Boige V; Ducreux M; Bonyhay L; Mansourbakht T; de Baere T; Asnacios A; Hannoun L; Poynard T; Taïeb J
    Cancer; 2007 Apr; 109(7):1384-90. PubMed ID: 17330837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.
    Von Burton G; Rankin C; Zalupski MM; Mills GM; Borden EC; Karen A
    Am J Clin Oncol; 2006 Feb; 29(1):59-61. PubMed ID: 16462504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.
    Park JS; Oh SY; Kim SH; Kwon HC; Kim JS; Jin-Kim H; Kim YH
    Jpn J Clin Oncol; 2005 Feb; 35(2):68-73. PubMed ID: 15709089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
    Van Kooten M; Traine G; Cinat G; Cazap E; Comba AZ; Vicente H; Sena S; Nievas OR; Orlando M
    Br J Cancer; 1999 Nov; 81(5):846-9. PubMed ID: 10555756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of gemcitabine in advanced sarcomas.
    Okuno S; Edmonson J; Mahoney M; Buckner JC; Frytak S; Galanis E
    Cancer; 2002 Jun; 94(12):3225-9. PubMed ID: 12115355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
    Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
    Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study.
    Lombardi G; Zustovich F; Farinati F; Cillo U; Vitale A; Zanus G; Donach M; Farina M; Zovato S; Pastorelli D
    Cancer; 2011 Jan; 117(1):125-33. PubMed ID: 21058409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.
    Casper ES; Green MR; Kelsen DP; Heelan RT; Brown TD; Flombaum CD; Trochanowski B; Tarassoff PG
    Invest New Drugs; 1994; 12(1):29-34. PubMed ID: 7960602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.